Experimental combo shows promise for Hard-to-Treat melanoma
Disease control
Completed
This phase 2 trial tested a combination of two drugs—BO-112, injected directly into tumors, and pembrolizumab, given through a vein—in 42 adults with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to see if the combo could shrink tumors and …
Phase: PHASE2 • Sponsor: Highlight Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC